| Methods of treating subjects with hepatitis B virus (HBV) infection |
2023-5-30 |
2023-9-05 |
|
| Compositions and methods for inhibiting expression of the ALAS1 gene |
2023-5-30 |
2023-8-29 |
|
| Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof |
2023-5-09 |
2023-7-19 |
|
| Lactate dehydrogenase A (LDHA) iRNA compositions and methods of use thereof |
2023-5-08 |
2023-8-16 |
|
| Biodegradable lipids for the delivery of active agents |
2023-4-20 |
2023-8-17 |
|
| PCSK9 iRNA compositions and methods of use thereof |
2023-4-19 |
2023-7-26 |
|
| Oligonucleotide-ligand conjugates and process for their preparation |
2023-4-03 |
2023-5-25 |
|
| Complement factor b (cfb) irna compositions and methods of use thereof |
2023-3-22 |
2023-8-17 |
|
| Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and … |
2023-2-22 |
2023-5-25 |
|
| TMPRSS6 iRNA compositions and methods of use thereof |
2023-2-21 |
2023-5-25 |
|
| Microtubule associated protein tau (mapt) irna agent compositions and methods … |
2023-2-10 |
2023-8-17 |
|
| Transthyretin (ttr) irna compositions and methods of use thereof for treating … |
2023-2-09 |
2023-2-28 |
|
| Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods … |
2023-1-23 |
2023-7-27 |
|
| Modified rna agents with reduced off-target effect |
2023-1-20 |
2023-4-13 |
|
| Compositions and methods for inhibition of expression of apolipoprotein c-iii ( … |
2023-1-13 |
2023-3-22 |
|
| Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
2023-1-12 |
2023-4-11 |
|
| Complement component C5 iRNA compositions and methods of use thereof |
2023-1-11 |
2023-4-13 |
|
| Multi-targeted single entity conjugates |
2023-1-10 |
2023-3-03 |
|
| TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE … |
2023-1-06 |
2023-7-13 |
|
| Modified Double-Stranded RNA Agents |
2022-12-22 |
2023-6-15 |
|
| iRNA COMPOSITIONS AND METHODS FOR SILENCING MYLIP |
2022-12-07 |
2023-6-15 |
|
| Modified rnai agents |
2022-12-06 |
2023-3-14 |
|
| Methods of treating transthyretin (ttr) mediated amyloidosis |
2022-12-01 |
2023-3-07 |
|
| Carbohydrate Conjugates as Delivery Agents for Oligonucleotides |
2022-11-22 |
2023-1-20 |
|
| Reversir (tm) compound |
2022-11-22 |
2023-2-07 |
|
| Endosomal-cleavable linkers |
2022-11-21 |
2023-1-20 |
|
| Complement factor b (cfb) arni compositions and methods of use thereof |
2022-11-11 |
2022-11-29 |
|
| Di-aliphatic substituted pegylated lipids |
2022-11-10 |
2023-2-02 |
|
| Branched alkyl and cycloalkyl terminated biodegradable lipids for delivery of … |
2022-11-09 |
2023-1-20 |
|
| Chirally-enriched double-stranded rna agents |
2022-11-08 |
2023-4-20 |
|
| HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
2022-10-27 |
2023-5-04 |
|
| APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
2022-10-27 |
2023-6-22 |
|
| Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides |
2022-10-19 |
2023-4-27 |
|
| Extra-hepatic delivery irna compositions and methods of use thereof |
2022-10-14 |
2023-4-20 |
|
| Compositions and methods for silencing scn9a expression |
2022-10-06 |
2022-12-01 |
|
| Compositions and methods for silencing myoc expression |
2022-10-06 |
2022-12-01 |
|
| Renal injury biomarkers as biomarkers for acute hepatic porphyria (ahp) |
2022-10-04 |
2023-4-13 |
|
| iRNA COMPOSITIONS AND METHODS FOR TARGETING ANGPTL7 |
2022-9-30 |
2023-4-06 |
|
| ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE … |
2022-9-30 |
2023-5-04 |
|
| Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use … |
2022-9-30 |
2023-6-22 |
|
| TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
2022-9-28 |
2023-4-13 |
|
| Composition and method for inhibiting expression of tmprss6 gene |
2022-9-28 |
2022-12-06 |
|
| HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
2022-9-28 |
2023-4-27 |
|
| Microtubule associated protein tau (mapt) irna agent compositions and methods … |
2022-9-28 |
2022-11-01 |
|
| Microtubule associated protein tau (mapt) irna agent compositions and methods … |
2022-9-23 |
2023-4-27 |
|
| Inhibin subunit beta e (inhbe) modulator compositions and methods of use … |
2022-9-19 |
2023-3-23 |
|
| Irna compositions and methods for silencing angptl4 |
2022-9-16 |
2023-3-23 |
|
| Rnai agents, compositions and methods of use thereof for treating transthyretin … |
2022-9-15 |
2022-12-01 |
|
| Irna compositions and methods for silencing complement component 3 (c3) |
2022-9-15 |
2023-4-27 |
|
| Compositions and methods for treating subjects having a heterozygous alanine- … |
2022-9-15 |
2023-6-15 |
|
| Compositions and methods to silence the expression of vegf–a |
2022-9-09 |
2022-12-09 |
|
| App irna compositions and methods of use thereof for treating or preventing … |
2022-9-09 |
2023-4-20 |
|
| Methods and compositions for treating a proprotein convertase subtilisin kexin … |
2022-9-08 |
2022-11-17 |
|
| Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
2022-9-01 |
2023-5-04 |
|
| COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR … |
2022-9-01 |
2023-8-31 |
|
| Cell death-inducing dffa-like effector b (cideb) irna compositions and methods … |
2022-8-31 |
2023-3-09 |
|
| Ketohexokinase (khk) irna compositions and methods of use thereof |
2022-8-31 |
2022-11-01 |
|
| Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 ( … |
2022-8-15 |
2023-4-20 |
|
| Factor xii (f12) irna compositions and methods of use thereof |
2022-8-12 |
2023-2-16 |
|
| Compositions and methods for silencing vegf-a expression. |
2022-8-10 |
2023-3-10 |
|
| iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT) |
2022-8-03 |
2023-2-09 |
|
| Methods and compositions for treating a bleeding event in a subject having … |
2022-8-01 |
2023-5-25 |
|
| Peptide ligands for cns and ocular delivery of rnai compounds |
2022-7-29 |
2023-2-02 |
|
| 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods … |
2022-7-28 |
2023-2-02 |
|
| Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
2022-7-27 |
2022-9-01 |
|
| COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS FOR USE IN THE TREATMENT OF … |
2022-7-26 |
2023-5-04 |
|
| Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
2022-7-21 |
2023-1-26 |
|
| Metabolic disorder-associated target gene irna compositions and methods of use … |
2022-7-20 |
2023-1-26 |
|
| Methods and compositions for treating subjects having or at risk of developing … |
2022-7-18 |
2023-1-26 |
|
| Multiplexing targeting ligands through click chemistry at the anomeric site of … |
2022-7-15 |
2023-1-19 |
|
| Simple chemical approaches to introduce 2,6-diaminopurine and 2-aminoadenine … |
2022-7-15 |
2023-1-19 |
|
| Human chromosome 9 open reading frame 72 (c9orf72) rni agents, compositions and … |
2022-7-13 |
2022-7-19 |
|
| Lipid containing formulations |
2022-7-13 |
2023-6-08 |
|
| Leucine-rich repeat kinase 2 (lrrk2) irna agent compositions and methods of use … |
2022-7-12 |
2022-9-01 |
|
| STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA … |
2022-7-08 |
2023-3-30 |
|
| Bis-rnai compounds for cns delivery |
2022-7-08 |
2023-4-13 |
|
| Aminooxy click chemistry (aocc): a versatile bioconjugation approach |
2022-7-08 |
2023-1-12 |
|
| Integrin targeting ligands for ocular delivery of rnai compounds |
2022-7-07 |
2023-2-09 |
|
| Carbohydrate conjugate rna agents and process for their preparation |
2022-7-05 |
2022-12-01 |
|
| Complement component irna compositions and methods of use thereof |
2022-7-03 |
2022-9-01 |
|
| ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
2022-7-01 |
2023-4-20 |
|
| FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 ( … |
2022-6-30 |
2022-9-29 |
|
| Compositions and methods for inhibiting expression of transthyretin |
2022-6-30 |
2022-10-19 |
|
| Methods and compositions for treating an angiotensinogen- (agt-) associated … |
2022-6-29 |
2023-1-05 |
|
| Leucine-rich repeat kinase 2 (lrrk2) irna agent compositions and methods of use … |
2022-6-29 |
2023-1-05 |
|
| SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR … |
2022-6-29 |
2022-11-10 |
|
| Compositions and methods for silencing myoc expression |
2022-6-28 |
2023-1-05 |
|
| Irna compositions and methods for silencing filamin a (flna) |
2022-6-23 |
2022-12-29 |
|
| Arni Compositions Containing a Patatin-Like Phospholipase 3 (pnpla3) Domain and … |
2022-6-14 |
2023-3-17 |
|
| Biodegradable lipids for the delivery of active agents |
2022-6-14 |
2022-6-30 |
|
| Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and … |
2022-6-13 |
2022-8-01 |
|
| Compositions and methods for inhibiting expression of the alas1 gene |
2022-6-12 |
2022-8-01 |
|
| Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
2022-6-10 |
2023-3-30 |
|
| Compositions and methods for treating or preventing stargardt's disease and/or … |
2022-6-06 |
2023-4-01 |
|
| Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and … |
2022-6-01 |
2022-12-08 |
|
| HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND … |
2022-5-31 |
2022-12-08 |
|
| Compositions and methods for the inhibition of gene expression of hao1 ( … |
2022-5-30 |
2023-3-24 |
|
| Compositions and methods for silencing carbonic anhydrase 2 expression |
2022-5-27 |
2023-1-12 |
|
| Carbohydrate conjugates as delivery agents for oligonucleotides |
2022-5-26 |
2022-6-16 |
|
| Synthesis of 3'-rna oligonucleotides |
2022-5-25 |
2022-7-01 |
|